|
1
|
Imai T, Toyota M, Suzuki H, et al:
Epigenetic inactivation of RASSF2 in oral squamous cell carcinoma.
Cancer Sci. 99:958–966. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Scully C and Bagan JV: Recent advances in
Oral Oncology 2007: imaging, treatment and treatment outcomes. Oral
Oncol. 44:211–215. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Cai ZG, Shi XJ, Gao Y, Wei MJ, Wang CY and
Yu GY: Beta-catenin expression pattern in primary oral squamous
cell carcinoma. Chin Med J (Engl). 121:1866–1870. 2008.PubMed/NCBI
|
|
4
|
Chen CH, Su CY, Chien CY, et al:
Overexpression of beta2-microglobulin is associated with poor
survival in patients with oral cavity squamous cell carcinoma and
contributes to oral cancer cell migration and invasion. Br J
Cancer. 99:1453–1461. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Shi C, Zhu Y, Su Y, Chung LW and Cheng T:
Beta2-microglobulin: emerging as a promising cancer therapeutic
target. Drug Discov Today. 14:25–30. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Winchester JF, Salsberg JA and Levin NW:
Beta-2 microglobulin in ESRD: an in-depth review. Adv Ren Replace
Ther. 10:279–309. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Margalit A, Sheikhet HM, Carmi Y, et al:
Induction of antitumor immunity by CTL epitopes genetically linked
to membrane-anchored beta2-microglobulin. J Immunol. 176:217–224.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Christianson GJ, Brooks W, Vekasi S, et
al: Beta 2-microglobulin-deficient mice are protected from
hypergammaglobulinemia and have defective antibody responses
because of increased IgG catabolism. J Immunol. 159:4781–4792.
1997.PubMed/NCBI
|
|
9
|
Hoglund P, Glas R, Menard C, et al:
Beta2-microglobulin-deficient NK cells show increased sensitivity
to MHC class I-mediated inhibition, but self tolerance does not
depend upon target cell expression of H-2Kb and Db heavy chains.
Eur J Immunol. 28:370–378. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huang WC, Wu D, Xie Z, et al:
Beta2-microglobulin is a signaling and growth-promoting factor for
human prostate cancer bone metastasis. Cancer Res. 66:9108–9116.
2006. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Nomura T, Huang WC, Zhau HE, et al:
Beta2-microglobulin promotes the growth of human renal cell
carcinoma through the activation of the protein kinase A, cyclic
AMP-responsive element-binding protein, and vascular endothelial
growth factor axis. Clin Cancer Res. 12:7294–7305. 2006. View Article : Google Scholar
|
|
12
|
Tsimberidou AM, Kantarjian HM, Wen S, et
al: The prognostic significance of serum beta2 microglobulin levels
in acute myeloid leukemia and prognostic scores predicting
survival: analysis of 1,180 patients. Clin Cancer Res. 14:721–730.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Huang WC, Havel JJ, Zhau HE, et al:
Beta2-microglobulin signaling blockade inhibited androgen receptor
axis and caused apoptosis in human prostate cancer cells. Clin
Cancer Res. 14:5341–5347. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Sdek P, Zhang ZY, Cao J, Pan HY, Chen WT
and Zheng JW: Alteration of cell-cycle regulatory proteins in human
oral epithelial cells immortalized by HPV16 E6 and E7. Int J Oral
Maxillofac Surg. 35:653–657. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhang L, Yang X, Zhong LP, et al:
Decreased expression of Annexin A1 correlates with pathologic
differentiation grade in oral squamous cell carcinoma. J Oral
Pathol Med. 38:362–370. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Kageshita T, Hirai S, Ono T, Hicklin DJ
and Ferrone S: Down-regulation of HLA class I antigen-processing
molecules in malignant melanoma: association with disease
progression. Am J Pathol. 154:745–754. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Klein B, Levin I, Kfir B, Mishaeli M,
Shapira J and Klein T: The significance of soluble interleukin-2,
soluble interleukin-2 receptors, soluble ICAM-1 and beta
2-microglobulin in breast cancer patients. Tumour Biol. 16:290–296.
1995. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Freeman MR: Beta2 microglobulin: a
surprising therapeutic target for prostate cancer and renal cell
carcinoma. J Urol. 178:10–11. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Nissen MH, Bjerrum OJ, Plesner T, Wilken M
and Rorth M: Modification of beta-2-microglobulin in sera from
patients with small cell lung cancer: evidence for involvement of a
serine protease. Clin Exp Immunol. 67:425–432. 1987.PubMed/NCBI
|
|
20
|
Kaplan B, Martin BM, Livoff A, Yeremenko
D, Livneh A and Cohen HIL: Gastrointestinal beta2microglobulin
amyloidosis in hemodialysis patients: biochemical analysis of
amyloid proteins in small formalin-fixed paraffin-embedded tissue
specimens. Mod Pathol. 18:1610–1617. 2005.
|
|
21
|
Lee JK, Tsai SC, Hsieh JF, Ho YJ, Sun SS
and Kao CH: Beta-2-microglobulin (beta 2M) as a tumor marker in
nasopharyngeal carcinoma. Anticancer Res. 20:4765–4768.
2000.PubMed/NCBI
|
|
22
|
Kim JE, Yoo C, Lee DH, Kim SW, Lee JS and
Suh C: Serum albumin level is a significant prognostic factor
reflecting disease severity in symptomatic multiple myeloma. Ann
Hematol. 89:391–397. 2009. View Article : Google Scholar
|
|
23
|
Delgado J, Pratt G, Phillips N, et al:
Beta2-microglobulin is a better predictor of treatment-free
survival in patients with chronic lymphocytic leukaemia if adjusted
according to glomerular filtration rate. Br J Haematol.
145:801–805. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Federico M, Guglielmi C, Luminari S, et
al: Prognostic relevance of serum beta2 microglobulin in patients
with follicular lymphoma treated with anthracycline-containing
regimens. A GISL study. Haematologica. 92:1482–1488. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Albitar M, Vose JM, Johnson MM, et al:
Clinical relevance of soluble HLA-I and beta2-microglobulin levels
in non-Hodgkin's lymphoma and Hodgkin's disease. Leuk Res.
31:139–145. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Sousa AO, Mazzaccaro RJ, Russell RG, et
al: Relative contributions of distinct MHC class I-dependent cell
populations in protection to tuberculosis infection in mice. Proc
Natl Acad Sci USA. 97:4204–4208. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Hicklin DJ, Wang Z, Arienti F, Rivoltini
L, Parmiani G and Ferrone S: Beta2-Microglobulin mutations, HLA
class I antigen loss, and tumor progression in melanoma. J Clin
Invest. 101:2720–2729. 1998. View
Article : Google Scholar : PubMed/NCBI
|
|
28
|
Mehta AM, Jordanova ES, Kenter GG, Ferrone
S and Fleuren GJ: Association of antigen processing machinery and
HLA class I defects with clinicopathological outcome in cervical
carcinoma. Cancer Immunol Immunother. 57:197–206. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
del Campo AB, Aptsiauri N, Mendez R, et
al: Efficient recovery of HLA class I expression in human tumor
cells after beta2-microglobulin gene transfer using adenoviral
vector: implications for cancer immunotherapy. Scand J Immunol.
70:125–135. 2009.PubMed/NCBI
|
|
30
|
Koene GJ, Arts-Hilkes YH, van der Ven KJ,
et al: High level of chromosome 15 aneuploidy in head and neck
squamous cell carcinoma lesions identified by FISH analysis:
limited value of beta2-microglobulin LOH analysis. Tissue Antigens.
64:452–461. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Feenstra M, Veltkamp M, van Kuik J, et al:
HLA class I expression and chromosomal deletions at 6p and 15q in
head and neck squamous cell carcinomas. Tissue Antigens.
54:235–245. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Yang J, Qian J, Wezeman M, et al:
Targeting beta2-microglobulin for induction of tumor apoptosis in
human hematological malignancies. Cancer Cell. 10:295–307. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Yang J, Zhang X, Wang J, et al:
Anti-beta2-microglobulin monoclonal antibodies induce apoptosis in
myeloma cells by recruiting MHC class I to and excluding growth and
survival cytokine receptors from lipid rafts. Blood. 110:3028–3035.
2007. View Article : Google Scholar
|
